2009年7月

論文の本文は厳密に分かれてはいませんが、内容的にはIMRADに準じています。すなわち、Introduction に続いて、検討する項目ごとに(大抵はパラグラフごとに)Methods, Results, (Discussion)が述べてあります。key words やresults を用いたSubheadings(小見出し)がついている場合もあります。最後に、全体のDiscussionとConclusion。今回は良く使われている表現ではなく、ちょっと使ってみたい表現を集めてみました。

1. 研究の動機を述べたいとき

1) これまで成功していない
Decades of effort have witnessed the failure of many chemotherapeutic regimens.
2) 他者の研究に触発された
 Inspired by -----/ encouraged by -----/ 
3) これまでの成果を述べたい
Previous efforts to ----- had yielded -----
4) --- に着目した
We focused on the ---

 

2. 次々に説明したいとき

1) Decision making, memory, and learning require activation and modification of particular synapses. Synaptic transmission in turn requires neurotransmitter accumulation into synaptic vesicles followed by neurotransmitter release during synaptic vesicle fusion with the plasma membrane.                                                          (Science 2009 [Jun.12]:324;1441)
2) We first examined ---. We then investigated ---. We next analyzed ---. Lastly, we performed ---.

 

2.  対比したいとき、whereas, while, than, compared with はよくご存じなので割愛します。

1) unlike
 Unlike other structurally characterized neutralizing antibodies, CR6261 binds at the
membrane proximal end of each HA, ---                 (Science 2009 [Apr. 10]:324; 246)
 2)  in contrast to
 Perhaps more unusually, HCDR3 contributes relatively little, in contrast to its usual
dominant role in antigen recognition.                       (Science 2009 [Apr. 10]:324; 246)

 

4.  予期したとおりに実験が進んだとき

1)  as expected/ as anticipated
2) The observation that --- was consistent with the model/prediction.

 

5.  優れている点を強調したいとき

1)  The disulfide cross-linked VP7 trimer, which binds neutralizing antibodies such as mAb 159, is a good first candidate for a more effective, stable, structurally engineered subunit immunogen.                                                                           (Science 2009 [Jun.12]:324; 1444)


2) Although ---, our results nonetheless may open new avenues for improving the delivery and efficacy of therapeutics in patients with pancreatic cancer.  
                                                                                                   (Science 2009 [Jun.12]:324; 1457)
 

3) Although ---, these results highlight a previously unknown link between the AAR pathway  and TH17-mediated immune-pathology.                         (Science 2009 [Jun.12]:324; 1334)
 

4) Our findings complement research in animal and clinical studies suggesting that VTA
BDNF is implicated in the pathogenesis of drug addiction. 
                                                                                                   (Science 2009 [Jun.26]:324; 1732)
 

5) This encourages hopes that OIH (opioid-induced hyperalgesia) may be targeted specifically without interfering with powerful opioid analgesia.   (Science 2009 [Jul.10]:325; 207)

 

本シリーズは今回で終了させていただきます。いい表現だなと思ったら、コピーしておき、忘れぬうちに使ってみましょう。Reviewゲートを通れば、言う事無し!
あなたの英語は、新しい変異を取り込んで進化したのです。それでは皆様、長い間有難うございました。